13F Pro13F Pro

Affinity Asset Advisors, LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1773195
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare98.5%$2.0B
  • Other0.8%$16.9M
  • Financials0.6%$12.8M

AUM History

13fpro.ai/research/fund/affinity-asset-advisors-llc-1773195

Conviction and streaks

Stable · top 10 = 42.6%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

ROIV$ROIVConviction hold6.5% weight · held 6 quartersAPGE$APGEConviction hold6.4% weight · held 10 quartersSYRE$SYREConviction hold5.5% weight · held 10 quartersXENE$XENEConviction hold4.7% weight · held 10 quartersERAS$ERASConviction hold4.7% weight · held 9 quartersROIV$ROIVAccumulating+2400% shares · 5 quarters runningAVTX$AVTXAccumulating+377% shares · 4 quarters runningCLDX$CLDXAccumulating+6906% shares · 4 quarters runningINSM$INSMAccumulating+44% shares · 2 quarters runningDNTH$DNTHAccumulating+248% shares · 2 quarters runningNUVL$NUVLTrimming-40% shares · 5 quarters runningTRVI$TRVITrimming-36% shares · 3 quarters runningOBIO$OBIOTrimming-95% shares · 3 quarters runningCYTK$CYTKTrimming-31% shares · 2 quarters runningABVX$ABVXTrimming-35% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/affinity-asset-advisors-llc-1773195

Affinity Asset Advisors, LLC 13F holdings — Q2 2026

$2.2B portfolio (+14.3% QoQ) · 113 holdings · Q2 2026 13F · top 10 are 43% of the stock portfolio

Includes $167.6M of put/call options ($55.1M puts, $112.6M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $2.0B. Weights use the stock portfolio.

All holdings — Affinity Asset Advisors, LLC (Q2 2026)

113 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
AVTX$AVTXAvalo Therapeutics, Inc.$53.6M+116%
CYTK$CYTKCYTOKINETICS INC$46.9M-21%
RVMD$RVMDRevolution Medicines, Inc.$46.8M+150%
ABVX$ABVXAbivax S.A.adr$44.0M-19%
TRAX$TRAXFirst Tracks Biotherapeutics, Inc.$40.9MNew
DNTH$DNTHDianthus Therapeutics, Inc. /DE/$39.0M+14%
STRO$STROSUTRO BIOPHARMA, INC.$38.9M+10%
MRNA$MRNAPUTModerna, Inc.$35.0MNew
NUVL$NUVLNuvalent, Inc.$34.0M-8%
TRVI$TRVITrevi Therapeutics, Inc.$33.6M-10%
MRNA$MRNACALLModerna, Inc.$33.3M-41%
— CALLARK ETF TR - GENOMIC REV ETF$31.5MNew
OVID$OVIDOvid Therapeutics Inc.$27.3M-5%
LXEO$LXEOLexeo Therapeutics, Inc.$27.0M+15%
CLDX$CLDXCelldex Therapeutics, Inc.$26.0M+40%

What changed in Q2 2026

Against the previous quarter's 13F: 23 new, 33 added to, 33 trimmed, 15 sold out. Share-count changes; largest moves by dollar size first.

New positions (23)

  • TRAX$TRAXFirst Tracks Biotherapeutics, Inc.$40.9M

    first bought this quarter

  • MRNA$MRNAPUTModerna, Inc.$35.0M

    first bought this quarter

  • CALLARK ETF TR - GENOMIC REV ETF$31.5M

    first bought this quarter

  • LLY$LLYCALLELI LILLY & Co$24.0M

    first bought this quarter

  • IDYA$IDYAIDEAYA Biosciences, Inc.$14.9M

    first bought this quarter

  • ODTX$ODTXOdyssey Therapeutics, Inc.$14.3M

    first bought this quarter

+17 more in the Excel export

Added to (33)

  • ROIV$ROIVRoivant Sciences Ltd.+34%

    now $132.7M · held 6 qtrs, 6 adds in a row

  • AVTX$AVTXAvalo Therapeutics, Inc.+116%

    now $53.6M · held 10+ qtrs, 4 adds in a row

  • RVMD$RVMDRevolution Medicines, Inc.+150%

    now $46.8M · held 4 qtrs

  • INSM$INSMINSMED Inc+35%

    now $69.3M · held 9 qtrs, 2 adds in a row

  • BLTE$BLTEBELITE BIO, INC+154%

    now $25.4M · held 3 qtrs, 3 adds in a row

  • SGMT$SGMTSagimet Biosciences Inc.+188%

    now $19.3M · held 4 qtrs

+27 more in the Excel export

Trimmed (33)

  • APGE$APGEApogee Therapeutics, Inc.-23%

    now $131.0M · held 10+ qtrs

  • TEVA$TEVATEVA PHARMACEUTICAL INDUSTRIES LTD-73%

    now $12.7M · held 10+ qtrs

  • MRNA$MRNACALLModerna, Inc.-41%

    now $33.3M

  • ASND$ASNDAscendis Pharma A/S-68%

    now $8.0M · held 3 qtrs

  • CYTK$CYTKCYTOKINETICS INC-21%

    now $46.9M · held 4 qtrs, 2 trims in a row

  • ALKS$ALKSAlkermes plc.-17%

    now $58.9M · held 10+ qtrs

+27 more in the Excel export

Sold out (15)

  • SPY$SPYPUTSPDR S&P 500 ETF TRUSTwas $130.1M
  • CNTA$CNTACentessa Pharmaceuticals plcwas $55.6M

    held 9+ qtrs

  • ACLX$ACLXArcellx, Inc.was $41.7M

    held 9+ qtrs

  • TERN$TERNTerns Pharmaceuticals, Inc.was $29.7M

    held 2 qtrs

  • BMY$BMYCALLBRISTOL MYERS SQUIBB COwas $18.2M
  • BBIO$BBIOBridgeBio Pharma, Inc.was $11.1M

    held 9+ qtrs

+9 more in the Excel export

Firm AUM (Form ADV): $2.5B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Affinity Asset Advisors, LLC has filed, 22 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Affinity Asset Advisors?

Q2 2026 13F filed with the SEC on Aug 13, 2026. Prices are closing prices as of Oct 27, 2026.

Average quality of Affinity Asset Advisors's top 20 holdings: 31/100 (our AI quality score, weighted by position size; 7 of the 20 are scored)

Top 10 since filing

-15.1%

Value-weighted move of the 10 largest stock positions

Turnover

19%

Last quarter; 93% over the last 4

Top 10 weight

43%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

75%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Affinity Asset Advisors, LLC disclosed 113 positions worth $2.2B in its Form 13F-HR for Q2 2026 — $2.0B in common stock plus $167.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ROIV (Roivant Sciences Ltd.) at 6.5% of the equity portfolio, followed by $APGE and $SYRE. During the quarter the fund opened 23 new positions and exited 15 — including a new stake in $TRAX and a full exit from $SPY. The portfolio is most concentrated in Healthcare (98.5% of disclosed assets). All figures are sourced directly from Affinity Asset Advisors, LLC’s Form 13F-HR filing with the SEC under CIK 1773195.

Funds like this

managers whose biggest positions overlap Affinity Asset Advisors's
PERCEPTIVE ADVISORS LLC$6.66B 13F book · 13 shared top holdingsSYREROIVPRAXAPGEParadigm Biocapital Advisors LP$5.34B 13F book · 10 shared top holdingsSYREAPGEERASORKAVR Adviser, LLC$3.30B 13F book · 11 shared top holdingsAPGESYREERASORKAFirst Turn Management, LLC$934.72M 13F book · 15 shared top holdingsROIVXENEINSMPRAXRTW INVESTMENTS, LP$11.71B 13F book · 11 shared top holdingsINSMSYREERASORKALogos Global Management LP$2.32B 13F book · 14 shared top holdingsERASPRAXRVMDABVX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Affinity Asset Advisors, LLC

13F Pro is an AI hedge fund tracker and stock research platform. For Affinity Asset Advisors, LLC (SEC CIK: 1773195), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Affinity Asset Advisors, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.